Keros Therapeutics, Inc.

KROSSEC EDGAR

Pharmaceutical PreparationsCIK: 1664710

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$3.5M	$0.00	$20.1M	$20.1M	$0.00
Research and Development Expense	$173.6M	$87.3M	$55.1M	$55.1M	$33.9M
Operating Expenses	$214.4M	$114.8M	$76.5M	$76.5M	$46.7M
Operating Income (Loss)	-$210.8M	-$114.8M	-$56.4M	-$56.4M	-$46.7M
Nonoperating Income (Expense)	$23.8M	$10.1M	-$360.0K	-$360.0K	$1.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$187.1M	-$104.7M	-$56.7M	-$56.7M	-$45.5M
Income Tax Expense (Benefit)	$300.0K	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$615.9M	$370.0M	$306.8M	$255.3M	$269.4M
Assets, Current	$588.9M	$347.3M	$285.8M	$251.4M	$267.7M
Cash and Cash Equivalents, at Carrying Value	$559.9M	$279.0M	$230.0M	$230.0M	$265.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.7M	$143.0K	$0.00	$18.0M	$0.00
Liabilities	$44.3M	$37.8M	$29.4M	$12.1M	$7.7M
Liabilities, Current	$27.4M	$24.4M	$16.5M	$11.8M	$7.2M
Accounts Payable, Current	$4.6M	$5.5M	$3.3M	$3.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$160.9M	-$70.1M	-$62.1M	-$62.1M	-$36.9M
Net Cash Provided by (Used in) Investing Activities	-$1.9M	-$1.2M	-$1.0M	-$1.0M	-$294.0K
Net Cash Provided by (Used in) Financing Activities	$391.8M	$120.3M	$28.6M	$28.6M	$296.0M
Payments to Acquire Property, Plant, and Equipment	$1.9M	$1.2M	$1.0M	$1.0M	$294.0K
Payments for Repurchase of Common Stock	$0.00	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)